S-E. Al-Batran

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Ö. Türeci, Uğur Şahin, Henning Schulze‐Bergkamen et al. · Annals of Oncology · 2019 · 244 citations · Full text

Medicine, Oncology, Pharmacology +17

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer

Sylvie Lorenzen, Claudia Pauligk, Nils Homann et al. · British Journal of Cancer · 2013 · 111 citations · Full text

Medicine, Oncology, Perioperative Medicine +14

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

Pauline Wimberger, Hélène Gilet, Ann-Katrin Gonschior et al. · Annals of Oncology · 2012 · 80 citations

Medicine, Internal Medicine, Oncology +11

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

S-E. Al-Batran, Wael Hozaeel, Felix Tauchert et al. · Annals of Oncology · 2015 · 65 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)

S-E. Al-Batran, Claudia Pauligk, Nils Homann et al. · Annals of Oncology · 2017 · 42 citations

Medicine, Oncology, Surgery +11